Hormonal
Concomitant administration of ixekizumab (IL-17A inhibitor) and tirzepatide (dual GIP/GLP-1 receptor agonist) achieves significantly greater disease control and weight loss in adults with psoriatic arthritis (PsA) and overweight/obesity compared to ixekizumab monotherapy.
For PsA patients who are overweight or obese, adding tirzepatide to ixekizumab therapy offers a dual benefit: significantly better joint symptom control and substantial weight loss, compared to using ixekizumab alone. This combination addresses both the inflammatory and metabolic aspects of the disease, leading to improved physical function and quality of life, with a safety profile consistent with the individual drugs.
The primary end point was achieved with significant improvements in the IXE + TZP arm (31.7%) compared to IXE alone (0.8%) (P < 0.001)... Greater improvements in ACR50 were demonstrated in IXE + TZP (33.5%) versus IXE alone (20.4%) (P = 0.02)
Why this rating
Phase 3b randomized clinical trial with 271 participants, statistically significant primary and secondary endpoints, and rigorous multiplicity control.
Source
Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial
Joseph F. Merola et al. · Arthritis & Rheumatology · 2026
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →